Skip to main content
IVVD
NASDAQ Life Sciences

Invivyd Receives 12-Month Notice of PEMGARDA EUA Termination from FDA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.84
Mkt Cap
$263.32M
52W Low
$0.483
52W High
$3.07
52W Position info
74% above low
Off High info
73% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

IVVD sits 74% above its 52-week low of $0.483.

Summary

Invivyd announced the FDA will terminate the Emergency Use Authorization for its COVID-19 antibody, PEMGARDA, by June 29, 2027, creating uncertainty for the product's future.


Key Events · Product Development and Regulatory · IVVD

  • EUA Termination Notice Received

    Invivyd received a 12-month advanced notice from the FDA regarding the termination of the Emergency Use Authorization (EUA) for PEMGARDA, effective June 29, 2027.

  • Regulatory Uncertainty for Key Product

    PEMGARDA, an investigational monoclonal antibody for COVID-19 prevention, has been authorized under EUA since March 2024 and is described as a critical non-vaccine option. Its future commercialization depends on securing full BLA approval.

  • Company Pursuing BLA Approval

    Invivyd is in active dialogue with the FDA to pursue a Biologics License Application (BLA) for PEMGARDA, stating it believes the product has sufficient clinical and post-authorization data to support approval.


Analysis · IVVD · Life Sciences

Invivyd's primary COVID-19 antibody, PEMGARDA, faces termination of its Emergency Use Authorization (EUA) by June 29, 2027. This creates significant regulatory uncertainty and could impact future revenue if the company fails to secure full Biologics License Application (BLA) approval within the transition period. The company states it is in active dialogue with the FDA to pursue a permanent approval pathway.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IVVD was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $263.3M. The 52-week trading range was $0.48 to $3.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IVVD - Latest Insights

IVVD
Nov 16, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.5867
Real-time Price: $0.5095 info
Change: -$0.0772 (-13%) info
Market Cap: $149.561M info
IVVD
Nov 16, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.562
Real-time Price: $0.5095 info
Change: -$0.0525 (-9%) info
Market Cap: $149.561M info
IVVD
Nov 16, 2026, 7:02 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.5731
Real-time Price: $0.5095 info
Change: -$0.0636 (-11%) info
Market Cap: $149.561M info
IVVD
Sep 29, 2026, 7:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9635
Real-time Price: $0.5095 info
Change: -$0.454 (-47%) info
Market Cap: $149.561M info
IVVD
Sep 29, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.16
Real-time Price: $0.5095 info
Change: -$0.6503 (-56%) info
Market Cap: $149.561M info